InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
0.00%
)
US TECH 100
19,215.20
(
0.27%
)
Dow Jones
39,118.86
(
0.00%
)
Brent Oil
85.67
(
0.65%
)
Bitcoin
62,825.86
(
0.36%
)
Post# of 252444
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 99206

Tuesday, 07/26/2011 6:25:14 PM

Tuesday, July 26, 2011 6:25:14 PM

Post# of 252444
GILD/JNJ—According to Thomas Wei of Jefferies, total US prescriptions for Edurant are only 200 (!), two months into the commercial launch. On GILD’s 2Q11 CC, Kevin Young (SVP, Commercial Ops) acknowledged that standalone Edurant will never garner significant sales; however, Young said GILD remains strongly committed to the launch of the ‘Btripla’ (Edurant + Truvada) combination pill, pending FDA approval. (The PDUFA date is 8/11/11.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up